Infinity Pharmaceuticals Inc (INFI)

1.44
NASDAQ : Health Care
Prev Close 1.36
Day Low/High 1.36 / 1.48
52 Wk Low/High 0.84 / 8.16
Avg Volume 522.00K
Exchange NASDAQ
Shares Outstanding 49.73M
Market Cap 67.63M
EPS -2.60
P/E Ratio 0.32
Div & Yield N.A. (N.A)

Latest News

Bristol-Myers Squibb And Infinity Pharmaceuticals Announce Clinical Collaboration To Evaluate Opdivo (Nivolumab) In Combination With IPI-549 In Advanced Solid Tumors

Bristol-Myers Squibb And Infinity Pharmaceuticals Announce Clinical Collaboration To Evaluate Opdivo (Nivolumab) In Combination With IPI-549 In Advanced Solid Tumors

-- Evaluation of IPI-549 as a Monotherapy Continuing, with Combination Portion of Phase 1 Study Expected to Begin This Fall --

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Verastem, Inc. (NASDAQ:VSTM) and Infinity Pharmaceuticals, Inc.

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Transaction Adds Complementary Late-Stage Product Candidate from a Clinically Validated Drug Class to Verastem's Pipeline

Short Interest Jumps 24.6% For INFI

Short Interest Jumps 24.6% For INFI

The most recent short interest data has been released for the 10/14/2016 settlement date, which shows a 408,920 share increase in total short interest for Infinity Pharmaceuticals Inc , to 2,067,803, an increase of 24.65% since 09/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Infinity Pharmaceuticals (INFI) Stock Rises on 'Favorable' Cancer Drug Trial Results

Infinity Pharmaceuticals (INFI) Stock Rises on 'Favorable' Cancer Drug Trial Results

Infinity Pharmaceuticals (INFI) said preliminary results from its IPI-549 drug trial showed that the cancer treatment can reverse tumor resistance to checkpoint inhibitors.

Infinity Announces Publication On PI3K-Gamma In Nature

Infinity Announces Publication On PI3K-Gamma In Nature

- PI3K-Gamma Identified as a Critical Molecular Switch that Controls Immune Suppression -

Infinity Regains Worldwide Rights To Duvelisib Following Mutual Agreement With AbbVie To End Collaboration

Infinity Regains Worldwide Rights To Duvelisib Following Mutual Agreement With AbbVie To End Collaboration

- Infinity to Explore Strategic Options for Duvelisib Program to Support Global Regulatory Filings for Duvelisib -

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Infinity Pharmaceuticals (INFI) Highlighted As Weak On High Volume

Infinity Pharmaceuticals (INFI) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a weak on high relative volume candidate

Infinity Pharmaceuticals Faces Downgrades as Drug Results Disappoint

Infinity Pharmaceuticals Faces Downgrades as Drug Results Disappoint

Analysts cut valuation estimates for Infinity Pharmaceuticals after a disappointing drug study.

Infinity Pharmaceuticals Cannot Cure Downgrades After Drug Study

Analysts cut valuation estimates after a disappointing drug study. 

Strong On High Volume: Infinity Pharmaceuticals (INFI)

Strong On High Volume: Infinity Pharmaceuticals (INFI)

Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a strong on high relative volume candidate

Why Infinity Pharmaceuticals (INFI) Stock Is Tanking Today

Why Infinity Pharmaceuticals (INFI) Stock Is Tanking Today

Infinity Pharmaceuticals (INFI) stock is plunging after the company announced a restructuring following disappointing drug-study results.

Morning Movers: BIDU, WGP, NERV, INFI

Stocks were falling slightly in premarket trading Tuesday as oil continued its six-day descent.

Infinity Reports Topline Results From DYNAMO™, A Phase 2 Monotherapy Study Of Investigational Molecule Duvelisib In Refractory Indolent Non-Hodgkin Lymphoma

Infinity Reports Topline Results From DYNAMO™, A Phase 2 Monotherapy Study Of Investigational Molecule Duvelisib In Refractory Indolent Non-Hodgkin Lymphoma

- Infinity and AbbVie in Discussions to Explore Possible Options for the Duvelisib Collaboration -

Infinity Announces Launch Of Disease Awareness Campaign For Hematologic Malignancies

Infinity Announces Launch Of Disease Awareness Campaign For Hematologic Malignancies

- Campaign Designed to Educate and Engage Community and Academic Oncologists on the Role of the Tumor Microenvironment in B-Cell Malignancies -

Infinity Announces Presentations On Investigational Development Candidates, Duvelisib And IPI-549, At Upcoming EHA And ASCO Meetings

Infinity Announces Presentations On Investigational Development Candidates, Duvelisib And IPI-549, At Upcoming EHA And ASCO Meetings

-- Preliminary Data from CONTEMPO, a Phase 1b/2 Combination Study Evaluating Duvelisib in Treatment-Naive Patients with Follicular Lymphoma, to Be Presented at EHA --